Target Name: GPR155
NCBI ID: G151556
Review Report on GPR155 Target / Biomarker Content of Review Report on GPR155 Target / Biomarker
GPR155
Other Name(s): GPR155 variant 2 | OTTHUMP00000163176 | GP155_HUMAN | GPR155 variant 4 | G protein-coupled receptor 155, transcript variant 3 | GPR155 variant 3 | FLJ39346 | DEPDC3 | Integral membrane protein GPR155 | G protein-coupled receptor 155 | DEP.7 | Integral membrane protein GPR155 (isoform 1) | PGR22 | G protein-coupled receptor 155, transcript variant 1 | G-protein coupled receptor PGR22 | GPR155 variant 1 | G protein-coupled receptor 155, transcript variant 4 | FLJ31819 | Integral membrane protein GPR155 (isoform 2) | G protein-coupled receptor 155, transcript variant 2

Targeting GPR155 for Drug Development and Biomarker Research

GPR155 (GPR155 variant 2) is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Its unique function and structure make it an attractive target for drug development, as scientists are increasingly discovering that many diseases are caused by the disruptions of normal cellular processes.

GPR155 is a non-coding RNA molecule that is expressed in many different tissues and cells in the body. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling.

GPR155 is known for its role in the regulation of pain perception and the development of neurodegenerative diseases. It is expressed in the central nervous system and is involved in the transmission of pain signals from the body to the brain. Studies have shown that GPR155 is involved in the regulation of pain perception and that it may play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its role in pain perception, GPR155 is also involved in the regulation of anxiety and depression. Studies have shown that GPR155 is involved in the regulation of anxiety and depression-related behaviors and that it may be a potential target for the treatment of these disorders.

GPR155 is also of interest as a potential biomarker for several diseases, including cancer. Studies have shown that GPR155 is expressed in a wide range of cancer types and that it may be involved in the regulation of cancer growth and progression. This makes it an attractive target for the development of new cancer therapies.

The GPR155 gene has also been the focus of research into its potential role in treating psychiatric disorders. Studies have shown that GPR155 is involved in the regulation of mood and that it may be a potential target for the treatment of mood disorders.

GPR155 is a small molecule that can be easily modified and targeted by drugs. This makes it an attractive target for drug development, as it allows researchers to test the effectiveness of new drugs on GPR155 and to identify potential new treatments for a wide range of disorders.

In conclusion, GPR155 is a gene that has the potential to be a drug target or biomarker for a wide range of disorders. Its unique function and structure make it an attractive target for research into the underlying mechanisms of these disorders and for the development of new treatments. Further research is needed to fully understand the role of GPR155 in the regulation of pain, anxiety, and depression, as well as its potential as a biomarker for cancer and psychiatric disorders.

Protein Name: G Protein-coupled Receptor 155

The "GPR155 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR155 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7